Summary: Centessa Pharmaceuticals has presented preclinical data on ORX142, an investigational orexin receptor 2 (OX2R) agonist, during the 27th Congress of the European Sleep Research Society. ORX142 demonstrated significant wake-promoting effects in non-human primates at very … [Read more...]
Centessa’s ORX142 Promotes Wakefulness in Preclinical Models
Summary: Centessa Pharmaceuticals announced that preclinical data from a non-human primate study of ORX142, an orexin receptor 2 (OX2R) agonist designed to address excessive daytime sleepiness (EDS) in various neurological, neurodegenerative, and psychiatric disorders, will be … [Read more...]